Published online May 31, 2019. doi: 10.13105/wjma.v7.i5.184
Peer-review started: March 19, 2019
First decision: May 18, 2019
Revised: May 25, 2019
Accepted: May 27, 2019
Article in press: May 28, 2019
Published online: May 31, 2019
Processing time: 74 Days and 15.1 Hours
As the second-most-common cause of cancer death, colorectal cancer (CRC) has been recognized as one of the biggest health concerns in advanced countries. The 5-year survival rate for patients with early-stage CRC is significantly better than that for patients with CRC detected at a late stage. The primary target for CRC screening and prevention is advanced neoplasia, which includes both CRC itself, as well as benign but histologically advanced adenomas that are at increased risk for progression to malignancy. Prevention of CRC through detection of advanced adenomas is important. It is, therefore, necessary to develop more efficient detection methods to enable earlier detection and therefore better prognosis. Although a number of CRC diagnostic methods are currently used for early detection, including stool-based tests, traditional colonoscopy, etc., they have not shown optimal results due to several limitations. Hence, development of more reliable screening methods is required in order to detect the disease at an early stage. New screening tools also need to be able to accurately diagnose CRC and advanced adenoma, help guide treatment, and predict the prognosis along with being relatively simple and non-invasive. As part of such efforts, many proposals for the early detection of colorectal neoplasms have been introduced. For example, metabolomics, referring to the scientific study of the metabolism of living organisms, has been shown to be a possible approach for discovering CRC-related biomarkers. In addition, a growing number of high-performance screening methodologies could facilitate biomarker identification. In the present, evidence-based review, the authors summarize the current state as recognized by the recent guideline recommendation from the American Cancer Society, US Preventive Services Task Force and the United States Multi-Society Task Force and discuss future direction of screening tools for colorectal cancer. Further, we highlight the most interesting publications on new screening tools, like molecular biomarkers and metabolomics, and discuss these in detail.
Core tip: A large proportion of colorectal cancer (CRC) cases and deaths could be prevented by screening with early detection and removal of colorectal adenomas or early stage CRC. Reliable and non-invasive screening tools for early stage CRC and precancerous lesions, such as adenoma is indispensable. However, current screening methods have limitations. Therefore, it is important to review the current literature on new screening tools such as molecular biomarkers and metabolomics for the development of new diagnostic tools.